Latest News and Press Releases

Phase 2 and Phase 3 trials are reshaping expectations across obesity, oncology, gene editing, autoimmune disease, and neurological disorders.

Biotechs continue attracting speculative capital as investors aggressively position around next-generation oncology, metabolic disease, and CNS therapy pla

The biologics sector is rapidly emerging as one of the most closely watched growth stories in healthcare $HCWB, $TGNT, $MRNA, $REGN

The U.S. housing and construction sector may be entering its next major consolidation cycle

Advanced materials science sits at the intersection of biology, chemistry, and engineering. $KBLB, $LHX, $HXL, $AVNT, $ASPN

The performance limits of aircraft, body armor, medical devices, and even semiconductors are ultimately governed by the physical properties of the materia

Cathie Wood and ARK Invest are making a decisive pivot that signals where the next phase of AI value creation may emerge: healthcare

Biotech and healthcare innovators are advancing novel therapies and strategic platforms amid rising demand for targeted treatments and efficient global ac

Emerging defense plays are capturing attention as geopolitical tensions drive investment into resilient supply chains, affordable drone defenses, and non-k

Recursion OS clinical trial Jensen Huang, NVIDIA’s (NASDAQ:NVDA) CEO, is now pointing to digital biology to be the next technological wave